The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | Bexobrutideg in CLL and approaching the sequencing of BTK degraders and inhibitors
In this video, Wojciech Jurczak, MD, PhD, Jagiellonian University, Krakow, Poland, briefly discusses the potential of BTK degraders, such as bexobrutideg, in chronic lymphocytic leukemia (CLL). Prof. Jurczak highlights that repeatedly blocking BTK pathways with multiple inhibitors may lead to resistance and suggests that using a BTK inhibitor followed by a BTK degrader may be a more effective approach. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
